Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2015-02-05 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
公司章程
Governance Information Classification · 95% confidence The document is a detailed company charter or articles of association (章程) for a Chinese joint-stock company, 中源协和细胞基因工程股份有限公司. It includes comprehensive provisions on company organization, shareholder rights, board of directors, shareholder meetings, share issuance, and governance rules. It is a foundational governance document rather than a financial report, earnings release, or announcement. It does not contain financial statements or audit opinions, nor is it a meeting presentation or voting result announcement. The content aligns with Governance Information (CGR) as it details the company's internal rules, board structure, shareholder meeting procedures, and governance practices.
2015-02-05 Chinese
关于修改公司章程的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding amendments to the company's articles of association, specifically changes to the board structure (number of vice chairmen). It is issued by the board and mentions approval by the board meeting and submission to the shareholders' meeting. There is no financial data, no report attached or referenced, and the content relates to governance structure changes. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2015-02-05 Chinese
关于与中国医学科学院血液病医院（血液学研究所）签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. about signing a strategic cooperation framework agreement with the Hematology Research Institute of the Chinese Academy of Medical Sciences. It details the cooperation purpose, content, obligations of both parties, and ongoing projects. The document is a formal announcement of a strategic partnership agreement, not a financial report, earnings release, or regulatory filing. It does not contain financial data, voting results, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. Therefore, the document best fits the category of a general regulatory announcement about a strategic cooperation agreement, which falls under Regulatory Filings (RNS).
2015-01-27 Chinese
关于发行股份及支付现金购买资产并募集配套资金暨关联交易之募集配套资金非公开发行股票发行情况报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a report on the issuance of shares and payment of cash to purchase assets, along with raising supporting funds through a non-public issuance of shares. It includes detailed sections on the issuance process, regulatory approvals, shareholding changes before and after issuance, financial data, and involvement of independent financial advisors, auditors, and legal counsel. The content is comprehensive and includes financial statements and management discussion and analysis related to the issuance and asset purchase transaction. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The focus on issuance of shares, capital raising, and related financial and procedural details aligns with a Capital/Financing Update filing rather than a simple announcement or other report types. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2015-01-26 Chinese
验资报告（瑞华验字[2015]12010001号）
Audit Report / Information Classification · 95% confidence The document is a detailed verification report (验资报告) issued by a certified public accountant firm (瑞华会计师事务所) regarding the capital increase and share capital changes of 中源协和细胞基因工程股份有限公司. It includes specifics about the registered capital before and after the increase, the issuance of shares to certain investors, and the valuation of contributed assets. The report references approvals from the China Securities Regulatory Commission and contains detailed tables of capital contributions and shareholder information. The document is lengthy (15,000 characters) and contains substantive financial and capital structure data, not merely an announcement or certification. This matches the characteristics of an Audit Report / Information (AR) as it is a standalone audit verification report on capital increase and share capital changes, not a full annual report or interim report. Therefore, the appropriate classification is AR with high confidence.
2015-01-26 Chinese
华英证券有限责任公司关于细胞基因工程股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易实施情况之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor's Verification Opinion" regarding a transaction involving issuance of shares and cash payment for asset acquisition and fundraising by Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It details the transaction structure, pricing, share issuance, fundraising, asset transfer, and compliance with regulatory approvals including the China Securities Regulatory Commission (CSRC). The document includes extensive information on the asset purchase, share issuance, fundraising, lock-up periods, and verification by the independent financial advisor. It is a detailed verification and implementation report on a major asset restructuring transaction involving issuance of shares and cash payment, which is typical of a Capital/Financing Update filing. It is not a full annual or interim report, nor an earnings release or proxy statement. It is not a simple announcement but a detailed verification opinion on the transaction implementation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (over 11,000 characters) and detailed content support this classification with high confidence.
2015-01-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.